Jacobs Levy Equity Management Inc. Cuts Position in Kodiak Sciences Inc. (NASDAQ:KOD)

Jacobs Levy Equity Management Inc. decreased its holdings in Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) by 37.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 360,476 shares of the company's stock after selling 220,307 shares during the period. Jacobs Levy Equity Management Inc. owned about 0.69% of Kodiak Sciences worth $3,587,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Barclays PLC boosted its holdings in shares of Kodiak Sciences by 65.5% in the 3rd quarter. Barclays PLC now owns 79,658 shares of the company's stock valued at $208,000 after purchasing an additional 31,527 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Kodiak Sciences by 220.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 44,648 shares of the company's stock valued at $117,000 after purchasing an additional 30,735 shares in the last quarter. Peapod Lane Capital LLC acquired a new stake in shares of Kodiak Sciences in the 4th quarter valued at $1,660,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Kodiak Sciences in the 4th quarter valued at $902,000. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Kodiak Sciences by 5.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 521,237 shares of the company's stock valued at $5,186,000 after purchasing an additional 26,058 shares in the last quarter. Institutional investors own 89.06% of the company's stock.

Kodiak Sciences Trading Up 6.5%

Kodiak Sciences stock traded up $0.24 during midday trading on Tuesday, reaching $3.95. The stock had a trading volume of 89,870 shares, compared to its average volume of 349,122. Kodiak Sciences Inc. has a 12 month low of $1.92 and a 12 month high of $11.60. The company has a market capitalization of $208.42 million, a P/E ratio of -1.08 and a beta of 2.42. The company has a fifty day moving average price of $3.28 and a two-hundred day moving average price of $5.50.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.20). On average, equities research analysts predict that Kodiak Sciences Inc. will post -3.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a "neutral" rating and issued a $3.00 price target on shares of Kodiak Sciences in a research note on Monday, March 31st.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.